Zejing Pharmaceutical (688266.SH): Gicacizidine hydrochloride tablets included in the 2025 National Medical Insurance Drug List.

Zejing Pharmaceutical (688266. SH) announced that on December 7, 2025, the National Medical Security Administration and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" (referred to as the "National Medical Insurance Drug List"). The independently developed hydrochloride Jixisitinib tablets of the company have been included in the National Medical Insurance Drug List through national medical insurance negotiations. The 2025 National Medical Insurance Drug List will be implemented from January 1, 2026. The inclusion of hydrochloride Jixisitinib tablets in the National Medical Insurance Drug List this time will be beneficial for product sales and have a positive impact on the company's long-term business development. It is expected that it will not have a significant impact on the company's operating performance in the short term.